Qu Biologics Inc.

Qu Biologies Inc.

David W Mullins

Harold David Gunn

Salim Dhanji

Shirin Kalyan

Mark Bazett

Dermot McGovern

Boyko Traychev Kabakchiev

Monan Angela Zhang

Ho Pan Sham

Momir Bosiljcic

Marcel Thalen

Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor.

Innate targeting of adoptive cellular therapies

The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.

Anti-microbial immunomodulation

The invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists, so that the pattern of PRR agonists recapitulates a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists may be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host, and the vehicle adapted to deliver the PRR agonists to the target tissue, so as to modulate an immune response.

Therapeutically triggering an innate immune response in a target tissue

Growing community of inventors

Lebanon, NH, United States of America

David W Mullins